Cutaneous squamous cell carcinoma - Eariy diagnosis and treatment are critical for a positive prognosis

摘要

The squamous cell carcinoma of the skin (cSCC) is one of the most frequent cancer types and counts for 20% of non-melanoma skin cancer. The diagnosis is based on clinical features and should be confirmed histopathologically to address the prognosis and treatment adequately. The first line treatment of cutaneous SCC is complete surgical excision with histopathological control of excision margins. In tumors with infiltration of deeper structures section imaging techniques are recommended to assess the extent of tumor growth. Although there is no clear evidence of its prognostic or therapeutic value, SLNB is recommended in tumors with a thickness of more than 6 mm. In positive lymph nodes a regional lymphnode dissection is recommended. Radiotherapy can be discussed in inoperable tumors or as an adjuvant therapy. In cSCC with distant metastases various chemotherapeutic agents are used, however, there is no standard regimen. EGFR inhibitors such as cetuximab or erlotinib, can be discussed as second line treatments or within the framework of clinical trials. There is no standardised follow-up schedule for patients with cSCC. A risk adapted follow-up is recommended based on the risk of metastatic spread or development of new lesions.